Toyota to invest $1B in Asian ride-sharing company Grab

UPI International Top News |

Toyota said Wednesday it will invest $1 billion in Grab Holdings, a Southeast Asian ride-hailing company similar to Uber and Lyft.

The deal comes as Grab seeks a new round of funding. The ride-sharing company, which acquired Uber's business in Southeast Asia earlier this year, is now valued at $10 billion.

For the investment, Toyota will receive a seat on Grab's board of directors, and the two companies will expand a collaboration started last year -- when the Japanese automaker put driving-data recorders, which are similar to flight recorders on commercial airlines, in Grab vehicles.

"The recorder, developed by Toyota for corporate fleets, has been installed in 100 Grab rental cars," Toyota said.

Singapore-based Grab has 100 million downloads of its ride-hailing app. It offers connections for rides, food delivery, mobile payments, on-demand bicycles and other services in 217 cities in eight Southeast Asian countries.

Grab called the deal the "largest-ever investment globally by an automotive manufacturer in the ride-hailing sector."

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments


Watchlist

Symbol Last Price Change % Change
AAPL

     
AMZN

     
HD

     
JPM

     
IBM

     
BA

     
WMT

     
DIS

     
XOM

     

World Economic Forum at Davos 2019 - Dr Oliver Krause Founder Untitled Inc Part 2

Matt Bird sits down with Dr Oliver Krause, Founder Untitled Inc, in part 2 of this 2 part interview at the World Economic Forum at Davos 2019

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.